Loading filters...
Publications per Year (4245 total)
17
1990
17
·
18
·
22
·
40
·
33
1995
39
·
61
·
46
·
62
·
69
2000
90
·
61
·
120
·
110
·
126
2005
125
·
118
·
128
·
143
·
121
2010
186
·
154
·
147
·
175
·
146
2015
201
·
192
·
179
·
184
·
163
2020
195
·
134
·
131
·
185
·
210
2025
97
·
Loaded
Click to load
50 / 4245 papers loaded(scroll for more)
202650 papers
AntiangiogenicAll Stages2026
ZW191, a FRα-targeted topoisomerase 1 inhibitor ADC with a differentiated antitumor efficacy and tolerability profile.
Lawn S et al. Clin Cancer Res. 2026
ImmunotherapyAll Stages2026
A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer.
Wenham RM et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination.
Ward MP et al. Br J Cancer. 2026
GeneralAll Stages2026
First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Wang Y et al. Gynecol Oncol. 2026
BRCA/HRDAll Stages2026
Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial.
Lafferty J et al. Int J Gynecol Cancer. 2026
BRCA/HRDAll Stages2026
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
Washington C et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer.
Tewari S et al. Gynecol Oncol. 2026
GeneralEarly (I-II)2026
Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.
Suleiman R et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial.
Krasny S et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-II)2026
Predictive features of anastomotic leakage after colorectal resection in complex multivisceral cytoreductive surgery for ovarian cancer.
Sorrentino L et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.
Smick AH et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Drew Y et al. Br J Cancer. 2026
GeneralAll Stages2026
Comparing nab-paclitaxel and solvent-based paclitaxel in platinum-resistant ovarian cancer: evidence and perspectives.
Sehouli J et al. Int J Gynecol Cancer. 2026
GeneralAdvanced (III-IV)2026
Multimodal prehabilitation improves functional capacity in patients with advanced ovarian cancer undergoing cytoreductive surgery.
Sebio-Garcia R et al. Int J Gynecol Cancer. 2026
AntiangiogenicAll Stages2026
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.
Yuan G et al. Nat Cancer. 2026
AntiangiogenicAdvanced (III-IV)2026
Improved progression-free survival with mirvetuximab and bevacizumab in platinum-resistant ovarian cancer: a retrospective real-world analysis.
Roberts JNT et al. Int J Gynecol Cancer. 2026
BRCA/HRDAll Stages2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).
Colombo N et al. Eur J Cancer. 2026
GeneralAll Stages2026
QLS5132 Goes after CLDN6 in Ovarian Cancer.
Cancer Discov. 2026
GeneralEarly (I-II)2026
Minimally invasive interval debulking surgery in advanced ovarian cancer: a real-life PICture of pAtientS' SelectiOn.
Conte C et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines.
Peplinski RM et al. Gynecol Oncol. 2026
AntiangiogenicAdvanced (III-IV)2026
Reassessing the risks: toxicity of stereotactic ablative radiotherapy after bevacizumab in oligometastatic ovarian cancer-a new perspective for radiation oncologists?
Pezzulla D et al. Int J Gynecol Cancer. 2026
AntiangiogenicAll Stages2026
Maintenance therapy for platinum-sensitive recurrent ovarian cancer with a history of PARPi administration.
Asano F et al. J Gynecol Oncol. 2026
BRCA/HRDAll Stages2026
G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity.
Ding M et al. Gynecol Oncol. 2026
BRCA/HRDEarly (I-II)2026
Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?
Bergeron AM et al. Gynecol Oncol. 2026
GeneralAdvanced (III-IV)2026
Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice.
Macdonald CJ et al. Br J Cancer. 2026
BRCA/HRDAll Stages2026
PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan.
Chao WT et al. J Gynecol Oncol. 2026
AntiangiogenicAll Stages2026
Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.
Cho HW et al. Clin Cancer Res. 2026
BRCA/HRDAdvanced (III-IV)2026
Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study.
Hayakawa M et al. Gynecol Oncol. 2026
BRCA/HRDAdvanced (III-IV)2026
Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification.
Kim JH et al. J Gynecol Oncol. 2026
AntiangiogenicAll Stages2026
Returning to PARP inhibition: Rechallenge with Bevacizumab in Ovarian Cancer.
Sachdeva M et al. Clin Cancer Res. 2026
GeneralEarly (I-II)2026
Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial.
Schreuder Goedheijt M et al. Gynecol Oncol. 2026
BRCA/HRDAdvanced (III-IV)2026
Impact of prior olaparib use on subsequent platinum-based therapy in recurrent ovarian cancer.
Ono K et al. J Gynecol Oncol. 2026
GeneralEarly (I-II)2026
Trends in the cost of ovarian cancer across phases of care and surgical years in Korea.
Oh BC et al. J Gynecol Oncol. 2026
GeneralAll Stages2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.
Tang X et al. Gynecol Oncol. 2026
BRCA/HRDAll Stages2026
Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer.
Nakayama J et al. Gynecol Oncol. 2026
GeneralAll Stages2026
MRI in advanced ovarian cancer: multicentre MISSION trial.
Berardi E et al. Eur J Cancer. 2026
GeneralEarly (I-II)2026
Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
Vandecaveye V et al. Br J Cancer. 2026
GeneralAdvanced (III-IV)2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.
Paracchini L et al. ESMO Open. 2026
GeneralEarly (I-II)2026
Association of surgical complexity with patient-reported outcomes among patients with ovarian cancer.
Liu JB et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Lee J et al. Gynecol Oncol. 2026
GeneralEarly (I-II)2026
Innovation through standardization: Reducing the ileostomy rates while targeting zero anastomotic leaks at cytoreductive surgery.
Langstraat CL et al. Gynecol Oncol. 2026
GeneralAll Stages2026
Symptom-triggered testing detects early stage and low volume resectable advanced stage ovarian cancer.
Kwong FLA et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.
Hayward S et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Survival impact and prognostic factors of secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a systematic review and trial-level meta-analysis.
Kim JH et al. Int J Gynecol Cancer. 2026
BRCA/HRDAdvanced (III-IV)2026
Comparison of survival outcomes and safety between early and late initiation of niraparib maintenance in newly diagnosed advanced epithelial ovarian cancer.
Kim SI et al. Int J Gynecol Cancer. 2026
GeneralAll Stages2026
Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.
Hoogstad-van Evert JS et al. Gynecol Oncol. 2026
GeneralAll Stages2026
PiggyBac-engineered membrane-bound IL-7 TILs combined with anti-PD-1 antibody demonstrates efficacy in recurrent ovarian cancer: a first-in-human phase 1 trial.
Guo J et al. Clin Cancer Res. 2026
AntiangiogenicAdvanced (III-IV)2026
Use of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: a Cancer Registry study.
Pfob A et al. Int J Gynecol Cancer. 2026
GeneralEarly (I-II)2026
Real-world use and outcomes of hyperthermic intra-peritoneal chemotherapy for stage III ovarian cancer.
Lot Aronson S et al. Int J Gynecol Cancer. 2026
BRCA/HRDAdvanced (III-IV)2026
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.
Kristeleit RS et al. Ann Oncol. 2026